Begin your TipRanks Premium journey today. BioCryst (BCRX) Company Description: BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes ...

On Monday, BioCryst Pharmaceuticals Inc (BCRX) stock saw a modest uptick, ending the day at $8.19 which represents a slight increase of $0.41 or 5.27% from the prior close of $7.78. The stock opened ...

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have earned a consensus recommendation of “Moderate ...

Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - ...

These unexpected attacks can also close off airways, potentially becoming fatal. Few treatments are available for this rare disorder but BioCryst Pharmaceuticals can now offer HAE patients another one ...

JP Morgan has recently resumed BioCryst Pharmaceuticals Inc (BCRX) stock to Overweight rating, as announced on November 20, 2023, according to Finviz. Earlier, on September 18, 2023, RBC Capital Mkts ...

A Durham company says its drug is pacing for over $400 million in revenue this year. The goal is $1 billion.

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced ...

Pharmaceuticals announced that the compensation committee of BioCryst’s board of directors granted five newly-hired ...

With dengue fever spreading to colder climates, Island Pharmaceuticals is working on a preventative and therapeutic solution.

Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Good day and Welcome to the BioCryst Third Quarter 2024 Earnings ...